Home » Psychology news » IV administration of endothelin B receptor drug reduces memory loss, oxidative stress in Alzheimer’s disease
IV administration of endothelin B receptor drug reduces memory loss, oxidative stress in Alzheimer’s disease
September 4, 2015 by NewsBot
An estimated 5.3 million people in the U.S. suffer from Alzheimer’s disease (AD). The five current FDA-approved AD medications only help mask the disease symptoms instead of treating the underlying disease. In a new study, researchers used IRL-1620, a chemical that binds to endothelin B receptors, to treat AD in rats.
